These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31044521)

  • 1. Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach.
    Zhou D; Podoll T; Xu Y; Moorthy G; Vishwanathan K; Ware J; Slatter JG; Al-Huniti N
    CPT Pharmacometrics Syst Pharmacol; 2019 Jul; 8(7):489-499. PubMed ID: 31044521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy.
    Chen B; Zhou D; Wei H; Yotvat M; Zhou L; Cheung J; Sarvaria N; Lai R; Sharma S; Vishwanathan K; Ware J
    Br J Clin Pharmacol; 2022 Aug; 88(8):3716-3729. PubMed ID: 35165925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
    Guo J; Zhou D; Li Y; Khanh BH
    Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
    Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
    Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically based pharmacokinetic combined BTK occupancy modeling for optimal dosing regimen prediction of acalabrutinib in patients alone, with different CYP3A4 variants, co-administered with CYP3A4 modulators and with hepatic impairment.
    Xu L; Yu S; Liu H; Yi B; Wang G; Liu Y
    Eur J Clin Pharmacol; 2022 Sep; 78(9):1435-1446. PubMed ID: 35680661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
    Prakash C; Fan B; Ke A; Le K; Yang H
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
    Wu F; Krishna G; Surapaneni S
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
    Yu Y; Loi CM; Hoffman J; Wang D
    J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
    Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
    Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
    Lin J; Goosen TC; Tse S; Yamagami H; Malhotra B
    J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator.
    Wang K; Yao X; Zhang M; Liu D; Gao Y; Sahasranaman S; Ou YC
    CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):441-454. PubMed ID: 33687157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
    Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
    Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
    Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
    Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
    Einolf HJ; Zhou J; Won C; Wang L; Rebello S
    Drug Metab Dispos; 2017 Apr; 45(4):361-374. PubMed ID: 28122787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.
    Watanabe A; Ishizuka T; Yamada M; Igawa Y; Shimizu T; Ishizuka H
    Eur J Clin Pharmacol; 2022 Jan; 78(1):65-73. PubMed ID: 34415382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices.
    Pepin XJH; Moir AJ; Mann JC; Sanderson NJ; Barker R; Meehan E; Plumb AP; Bailey GR; Murphy DS; Krejsa CM; Andrew MA; Ingallinera TG; Slatter JG
    Eur J Pharm Biopharm; 2019 Sep; 142():435-448. PubMed ID: 31306750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
    Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
    Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir.
    Stader F; Battegay M; Marzolini C
    Clin Pharmacol Ther; 2021 Nov; 110(5):1231-1239. PubMed ID: 33626178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
    Patel A; Wilson R; Harrell AW; Taskar KS; Taylor M; Tracey H; Riddell K; Georgiou A; Cahn AP; Marotti M; Hessel EM
    Drug Metab Dispos; 2020 Apr; 48(4):307-316. PubMed ID: 32009006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies.
    Edlund H; Lee SK; Andrew MA; Slatter JG; Aksenov S; Al-Huniti N
    Clin Pharmacokinet; 2019 May; 58(5):659-672. PubMed ID: 30556110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.